Pancreatic trypsin (PRSS)

Pancreatic trypsins, primarily comprising the isoforms Trypsin-1 (PRSS1), Trypsin-2 (PRSS2), and Trypsin-3 (PRSS3), are essential serine proteases synthesized as inactive zymogens in the pancreatic acinar cells [UniProt P07477, P07478]. Upon secretion into the duodenum, they are activated by enteropeptidase and subsequently trigger a cascade of activation for other pancreatic enzymes like chymotrypsin and elastase [StatPearls, 2023]. In healthy states, these enzymes are strictly regulated by endogenous inhibitors like SPINK1 to prevent premature activation within the pancreas. However, genetic mutations or ductal obstructions can lead to intra-pancreatic activation, causing autodigestion and the inflammatory condition known as pancreatitis [NIH, 2022]. Pharmacological targeting of these proteases with synthetic inhibitors like camostat or nafamostat aims to reduce tissue damage and systemic inflammatory responses during acute episodes [PubChem, CID 2536]. Additionally, these enzymes have gained attention in virology as certain viruses utilize host serine proteases for viral entry and spike protein priming [PubMed, PMID 32142651].

Other names

TrypsinogenCationic trypsinogenAnionic trypsinogenMesotrypsinogenSerine protease 1Serine protease 2Serine protease 3PRSS1PRSS2PRSS3

Inhibition of the catalytic serine residue within the active site of trypsin and related proteases, preventing the activation of the digestive enzyme cascade and reducing tissue autodigestion [PubChem, CID 2536; PubMed, PMID 32304143].